The Biologics Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Active R&D and Focus on Clinical Trials is Boosting the Biologics Market Growth
Active R&D and focus on clinical trials is driving the global biologics market growth. These R&D operations have resulted in increased success rates in biologic clinical studies. Industry leaders in the biologics market do R&D as they strive to produce market innovations in the form of effective and innovative biologics. Companies in the biologics sector have huge profit margins because of the high pricing of biologics and their efficacy. For decades, pharmaceutical corporations have focused on small compounds, but the rate of discovery in that sector has slowed drastically, resulting in a move toward biologics. Biologics therapy, which is roughly 20 times more expensive than small molecules, is predicted to create a profit margin of about 40%-45% in the future.
Logistical and Administrative Challenges
Governments and regulatory agencies play important roles in the biologics sector. Regulatory bodies maintain regulatory procedures for the development of new biologics markets for both existing and novel pharmaceuticals. Over the last decade, drug researchers have faced an increasing pushback in major markets for clinical studies of innovative biologics, which has hindered the launch of novel treatments for rare diseases. Strategic measures have been taken in these large markets, such as the United States and the European Union, to strengthen and liberalise regulatory regulations, hence simplifying clinical trial design. However, an increase in government spending for drug-related healthcare programmes is critical to industry success.
What Questions Should You Ask before Buying a Market Research Report?
• How is the biologics market evolving?
• What is driving and restraining the biologics market?
• How will each biologics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
• How will the market shares for each biologics submarket develop from 2022 to 2032?
• What will be the main driver for the overall market from 2022 to 2032?
• Will leading biologics markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
• Who are the leading players and what are their prospects over the forecast period?
• What are the biologics projects for these leading companies?
• How will the industry evolve during the period between 2022 and 2032? What is the implication of biologics projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the biologics market?
• Where is the biologics market heading? And how can you ensure you are at the forefront of the market?
• What can be the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the biologics market today, and over the next 10 years:
• Our 475-page report provides 308 tables and 320 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• Contains in-depth analysis of global, regional and national sales and growth
• Highlights for you the key successful trends, changes and revenue projections made by your competitors
This report tells you TODAY how the biologics market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Delivers exclusive COVID-19 variations economic data specific to your market.
Forecasts to 2032 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising biologics prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.
Segments Covered in the Report
Product Type
• Monoclonal Antibodies
• Vaccines
• Protein Therapeutics
• Fusion Proteins
• Regenerative Medicine
Application
• Oncology
• Autoimmune Disorder
• Infectious Diseases
• Cardiovascular Disorders
• Hematological Disorders
• Others
Manufacturing
• Outsourced
• In-house
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
North America
• U.S.
• Canada
Europe
• Germany
• UK
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific
Latin America
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa
• GCC
• South Africa
• Rest of MEA
The report also includes profiles for some of the leading companies in the Biologics Market, 2022 to 2032, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
• AbbVie Inc.
• Amgen Inc.
• Biogen
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline plc.
• Johnson & Johnson Services, Inc.
• Merck KGaA
• Novartis AG
• NuVasive, Inc.
• Novo Holdings A/S (Novo Nordisk A/S)
• Organogenesis Holdings Inc.
• ORTHOFIX INTERNATIONAL N.V.
• Pfizer Inc.
• Sanofi
• Takeda Pharmaceutical Company Limited
Overall world revenue for Biologics Market, 2022 to 2032 in terms of value the market will surpass US$382.85 billion in 2022, our work calculates. We predict strong revenue growth through 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Biologics Market, 2022 to 2032 Market report helps you?
In summary, our 470+ page report provides you with the following knowledge:
• Revenue forecasts to 2032 for Biologics Market, 2022 to 2032 Market, with forecasts for product type, application, and manufacturing each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2032 for 5 regional and 22 key national markets – See forecasts for the Biologics Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 18 of the major companies involved in the Biologics Market, 2022 to 2032.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our new report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Biologics Market, 2022 to 2032 Market and leading companies. You will find data, trends and predictions.
'
1. Report Overview
1.1 Introduction to Biologics Market
1.2 Biologics Market Definition
1.3 Why You Should Read This Report
1.4 What This Report Delivers
1.5 Key Questions Answered By This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Primary Research
1.7.2 Secondary Research
1.7.3 Market Evaluation & Forecasting Methodology
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About
2 Executive Summary
3 Market Dynamics
3.1 Drivers
3.1.1 Advancements in Biomedical Science
3.1.2 Increasing Funding for the Development of Novel Biologic Drugs
3.1.3 Several Drugs Going Off Patents
3.2 Restraints
3.2.1 High Stringency and Low Turnover for Clinical Trials
3.2.2 Development of Biosimilars will Reduce the Demand for Biological Drugs
3.3 Opportunities
3.3.1 Biologic Therapies are Becoming Relevant in a Greater Number of Disease Areas
3.4 Challenges
3.4.1 Complexity in Development of Biologics
3.5 SWOT Analysis
3.5.1 Strengths
3.5.1.1 Rising Need for Effective biologics Absorption and Convenient Self-Administration Emphasizes the Importance of the R&D Investment
3.5.2 Weaknesses
3.5.2.1 Financial Loss Due To Innovative Biologics Failure Has Been a Perennial Problem
3.5.3 Opportunities
3.5.3.1 Strong pipeline products and huge number of ongoing clinical trials are providing market growth opportunity.
3.5.3.2 Application of Nanotechnology in future
3.5.4 Threats
3.5.4.1 Small Molecules
3.6 Porter’s Five Forces Analysis
3.6.1 Bargaining Power of Supplier: High
3.6.2 Bargaining Power of Buyers: Moderate
3.6.3 Competitive Rivalry: High
3.6.4 Threat of New Entrants: Moderate
3.6.5 Threat of Substitutes: Low
3.7 PEST Analysis
3.7.1 Political Factors Impacting Biologics Market
3.7.2 Economic Factors Impacting Biologics Market
3.7.3 Social Factors Impacting Biologics Market
3.7.4 Technological Factors Impacting Biologics Market
4 Biologics Market by Product Type Forecast, 2022-2032
4.1 Monoclonal Antibodies Segment Market Forecast, 2022-2032
4.1.1 Monoclonal Antibodies: Holds Largest Market Share
4.1.2 Recovery Scenarios (V, U, W, L)
4.2 Vaccine Segment Market Forecast, 2022-2032
4.2.1 Vaccine Manufacturing Remains Concentrated, With Four Large Manufacturers
4.2.2 Recovery Scenarios (V, U, W, L)
4.3 Protein Therapeutics Segment Market Forecast, 2022-2032
4.3.1 Increased public knowledge of the benefits of protein therapies
4.3.2 Recovery Scenarios (V, U, W, L)
4.4 Regenerative Medicines Segment Market Forecast, 2022-2032
4.4.1 Government policies favouring Regenerative Medicines
4.4.2 Recovery Scenarios (V, U, W, L)
4.5 Fusion Proteins Segment Market Forecast, 2022-2032
4.5.1 Rising prevalence of diabetes expected to boost demand of fusion proteins
4.5.2 Recovery Scenarios (V, U, W, L)
5 Biologics Market by Application Forecast, 2022-2032
5.1 Oncology Segment Market Forecast, 2022-2032
5.1.1 Biological cancer therapy aims to train the immune system to recognise and kill cancer cells
5.1.2 Recovery Scenarios (V, U, W, L)
5.2 Autoimmune Diseases Segment Market Forecast, 2022-2032
5.2.1 Increasing Research and Development in this segment
5.2.2 Recovery Scenarios (V, U, W, L)
5.3 Infectious Diseases Therapeutics Segment Market Forecast, 2022-2032
5.3.1 Possible alternative to oral and parenteral routes of administration
5.3.2 Recovery Scenarios (V, U, W, L)
5.4 Cardiovascular Diseases Segment Market Forecast, 2022-2032
5.4.1 Cardiovascular Disorders is becoming the top cause of death worldwide
5.4.2 Recovery Scenarios (V, U, W, L)
5.5 Haematological Disorders Segment Market Forecast, 2022-2032
5.5.1 Blood disorders became a worldwide health issue
5.5.2 Recovery Scenarios (V, U, W, L)
5.6 Others Segment Market Forecast, 2022-2032
5.6.1 Adoption Haematological Disorders Technologies is expected to boost the Others Segment Growth
5.6.2 Recovery Scenarios (V, U, W, L)
6 Biologics Market by Manufacturing Forecast, 2022-2032
6.1 In-house Segment Market Forecast, 2022-2032
6.1.1 In-house holds largest Revenue market share
6.1.2 Recovery Scenarios (V, U, W, L)
6.2 Outsourced Segment Market Forecast, 2022-2032
6.2.1 Ease of use of Topical drug delivery to boost the outsourced market
6.2.2 Recovery Scenarios (V, U, W, L)
7 Global Biologics Market Forecast, 2022-2032
7.1 Global Biologics Market by Region Forecast 2022-2032
7.2 Recovery Scenarios (V, U, W, L)
8 North America Biologics Market, 2022-2032
8.1 Largest share acquired by North America in Global Biologics Market
8.2 North America Biologics Market by Country, Forecast 2022-2032
8.3 North America Biologics Market Forecast by Product Type
8.3.1 Recovery Scenarios (V, U, W, L): North America Biologics Market Forecast by Product Type, 2022-2032
8.4 North America Biologics Market Forecast by Application
8.4.1 Recovery Scenarios (V, U, W, L): North America Biologics Market Forecast by Application, 2022-2032
8.5 North America Biologics Market Forecast by Manufacturing
8.5.1 Recovery Scenarios (V, U, W, L): North America Biologics Market Forecast by Manufacturing, 2022-2032
8.6 U.S. Biologics Market Forecast, 2022-2032
8.6.1 Growing public and private funding for research studies in this region
8.6.2 Budget request for Pandemic preparedness
8.6.3 Recovery Scenarios (V, U, W, L): U.S. Biologics Market Forecast, 2022-2032
8.7 Canada Biologics Market Forecast, 2022-2032
8.7.1 Growing Prevalence of Psoriasis and Related Research and Development across the Region
8.7.2 Biologics represent a large segment of drug spending in Canada
8.7.3 Recovery Scenarios (V, U, W, L): Canada Biologics Market Forecast, 2022-2032
9 Europe Biologics Market, 2022-2032
9.1 Launch of Advanced Biologics across the Region
9.2 Europe Biologics Market by Country, Forecast 2022-2032
9.3 Europe Biologics Market Forecast by Product Type
9.3.1 Recovery Scenarios (V, U, W, L): Europe Biologics Market Forecast by Product Type, 2022-2032
9.4 Europe Biologics Market Forecast by Application
9.4.1 Recovery Scenarios (V, U, W, L): Europe Biologics Market Forecast by Application, 2022-2032
9.5 Europe Biologics Market Forecast by Manufacturing
9.5.1 Recovery Scenarios (V, U, W, L): Europe Biologics Market Forecast by Manufacturing, 2022-2032
9.6 Germany Biologics Market Forecast, 2022-2032
9.6.1 German government support market player for product development
9.6.2 Recovery Scenarios (V, U, W, L): Germany Biologics Market Forecast, 2022-2032
9.7 U.K. Biologics Market Forecast, 2022-2032
9.7.1 Increase in prevalence of diabetes and skin conditions
9.7.2 Recovery Scenarios (V, U, W, L): U.K. Biologics Market Forecast, 2022-2032
9.8 France Biologics Market Forecast, 2022-2032
9.8.1 Growing cancer prevalence and French government cancer control strategy
9.8.2 Recovery Scenarios (V, U, W, L): France Biologics Market Forecast, 2022-2032
9.9 Italy Biologics Market Forecast, 2022-2032
9.9.1 Rising prevalence of cancer
9.9.2 Recovery Scenarios (V, U, W, L): Italy Biologics Market Forecast, 2022-2032
9.10 Spain Biologics Market Forecast, 2022-2032
9.10.1 Growing burden of Infectious diseases
9.10.2 Recovery Scenarios (V, U, W, L): Spain Biologics Market Forecast, 2022-2032
9.11 Russia Biologics Market Forecast, 2022-2032
9.11.1 Major leap forward in terms of Digitalization
9.11.2 Recovery Scenarios (V, U, W, L): Russia Biologics Market Forecast, 2022-2032
9.12 Rest of Europe Biologics Market Forecast, 2022-2032
9.12.1 Rising Adoption of Advanced Biologics
9.12.2 Recovery Scenarios (V, U, W, L): Rest of Europe Biologics Market Forecast, 2022-2032
10 Asia Pacific Biologics Market, 2022-2032
10.1 Biologics APAC will emerge as the fastest growing regional market for biologics market R&D and production
10.2 Asia Pacific Biologics Market by Country, Forecast 2022-2032
10.3 Asia Pacific Biologics Market Forecast by Product Type
10.3.1 Recovery Scenarios (V, U, W, L): Asia Pacific Biologics Market Forecast by Product Type, 2022-2032
10.4 Asia Pacific Biologics Market Forecast by Application
10.4.1 Recovery Scenarios (V, U, W, L): Asia Pacific Biologics Market Forecast by Application, 2022-2032
10.5 Asia Pacific Biologics Market Forecast by Manufacturing
10.5.1 Recovery Scenarios (V, U, W, L): Asia Pacific Biologics Market Forecast by Manufacturing, 2022-2032
10.6 Japan Biologics Market Forecast, 2022-2032
10.6.1 Major market players investing on R&D
10.6.2 Recovery Scenarios (V, U, W, L): Japan Biologics Market Forecast, 2022-2032
10.7 China Biologics Market Forecast, 2022-2032
10.7.1 Rapid growth of Domestic mAb pipeline and regulatory reform is creating business opportunities for Biologics CDMO’s in China
10.7.2 Recovery Scenarios (V, U, W, L): China Biologics Market Forecast, 2022-2032
10.8 India Biologics Market Forecast, 2022-2032
10.8.1 India Biologics market currently is dominated by Simple Biologics
10.8.2 Recovery Scenarios (V, U, W, L): India Biologics Market Forecast, 2022-2032
10.9 Australia Biologics Market Forecast, 2022-2032
10.9.1 Growing capital investment by the market player
10.9.2 Recovery Scenarios (V, U, W, L): Australia Biologics Market Forecast, 2022-2032
10.10 South Korea Biologics Market Forecast, 2022-2032
10.10.1 Increasing prevalence of Cancer in South Korea
10.10.2 Recovery Scenarios (V, U, W, L): South Korea Biologics Market Forecast, 2022-2032
10.11 Rest of Asia Pacific Biologics Market Forecast, 2022-2032
10.11.1 Rising Disposable Income in this region
10.11.2 Recovery Scenarios (V, U, W, L): Rest of Asia Pacific Biologics Market Forecast, 2022-2032
11 Latin America Biologics Market, 2022-2032
11.1 Latin America Biologics Market expected to grow at lucrative CAGR
11.2 Latin America Biologics Market by Country, Forecast 2022-2032
11.3 Latin America Biologics Market Forecast by Product Type
11.3.1 Recovery Scenarios (V, U, W, L): Latin America Biologics Market Forecast by Product Type, 2022-2032
11.4 Latin America Biologics Market Forecast by Application
11.4.1 Recovery Scenarios (V, U, W, L): Latin America Biologics Market Forecast by Application, 2022-2032
11.5 Latin America Biologics Market Forecast by Manufacturing
11.5.1 Recovery Scenarios (V, U, W, L): Latin America Biologics Market Forecast by Manufacturing, 2022-2032
11.6 Brazil Biologics Market Forecast, 2022-2032
11.6.1 High Potential Manufacturing Environment
11.6.2 Recovery Scenarios (V, U, W, L): Brazil Biologics Market Forecast, 2022-2032
11.7 Mexico Biologics Market Forecast, 2022-2032
11.7.1 Lower Manufacturing Cost in Mexico
11.7.2 Recovery Scenarios (V, U, W, L): Mexico Biologics Market Forecast, 2022-2032
11.8 Rest of Latin America Biologics Market Forecast, 2022-2032
11.8.1 Developing Healthcare Infrastructure in this region
11.8.2 Recovery Scenarios (V, U, W, L): Rest of Latin America Biologics Market Forecast, 2022-2032
12 MEA Biologics Market, 2022-2032
12.1 Increasing occurrence of Cancer in this region
12.2 MEA Biologics Market by Country, Forecast 2022-2032
12.3 MEA Biologics Market Forecast by Product Type
12.3.1 Recovery Scenarios (V, U, W, L): MEA Biologics Market Forecast by Product Type, 2022-2032
12.4 MEA Biologics Market Forecast by Application
12.4.1 Recovery Scenarios (V, U, W, L): MEA Biologics Market Forecast by Application, 2022-2032
12.5 MEA Biologics Market Forecast by Manufacturing
12.5.1 Recovery Scenarios (V, U, W, L): MEA Biologics Market Forecast by Manufacturing, 2022-2032
12.6 GCC Biologics Market Forecast, 2022-2032
12.6.1 Presence of Hug Growth Opportunities
12.6.2 Recovery Scenarios (V, U, W, L): GCC Biologics Market Forecast, 2022-2032
12.7 South Africa Biologics Market Forecast, 2022-2032
12.7.1 Rapidly increasing infectious diseases in this South Africa
12.7.2 Recovery Scenarios (V, U, W, L): South Africa Biologics Market Forecast, 2022-2032
12.8 Rest of MEA Biologics Market Forecast, 2022-2032
12.8.1 Cancer is one of the main reason of Death causes in Rest of MEA
12.8.2 Recovery Scenarios (V, U, W, L): Rest of MEA Biologics Market Forecast, 2022-2032
13 Company Profiles
13.1 Company Share Analysis
13.2 Biologics Market Recent Developments
13.3 Johnson & Johnson Services, Inc.
13.3.1 Company Snapshot
13.3.2 Company Overview
13.3.3 Financial Analysis
13.3.3.1 Net Revenue, 2017-2021
13.3.3.2 Regional Revenue/Market Shares, 2021
13.3.3.3 Segmental Revenue/Market Shares, 2021
13.3.4 Product Benchmarking
13.3.5 Recent Developments
13.4 Merck KGaA
13.4.1 Company Snapshot
13.4.2 Company Overview
13.4.3 Financial Analysis
13.4.3.1 Net Revenue, 2017-2021
13.4.3.2 Regional Revenue/Market Shares, 2021
13.4.3.3 Segmental Revenue/Market Shares, 2021
13.4.4 Product Benchmarking
13.4.5 Recent Developments
13.5 GlaxoSmithKline plc.
13.5.1 Company Snapshot
13.5.2 Company Overview
13.5.3 Financial Analysis
13.5.3.1 Net Revenue, 2017-2021
13.5.3.2 Regional Revenue/Market Shares, 2021
13.5.3.3 Segmental Revenue/Market Shares, 2021
13.5.4 Product Benchmarking
13.5.5 Recent Developments
13.6 Novartis AG
13.6.1 Company Snapshot
13.6.2 Company Overview
13.6.3 Financial Analysis
13.6.3.1 Net Revenue, 2017-2021
13.6.3.2 Regional Revenue/Market Shares, 2021
13.6.3.3 Segmental Revenue/Market Shares, 2021
13.6.4 Product Benchmarking
13.6.5 Recent Developments
13.7 F. Hoffmann-La Roche Ltd
13.7.1 Company Snapshot
13.7.2 Company Overview
13.7.3 Financial Analysis
13.7.3.1 Net Revenue, 2017-2021
13.7.3.2 Segmental Revenue/Market Shares, 2021
13.7.3.3 Regional Revenue/Market Shares, 2020
13.7.4 Product Benchmarking
13.7.5 Recent Developments
13.8 Pfizer Inc.
13.8.1 Company Snapshot
13.8.2 Company Overview
13.8.3 Financial Analysis
13.8.3.1 Net Revenue, 2017-2021
13.8.3.2 Regional Revenue/Market Shares, 2021
13.8.3.3 Segmental Revenue/Market Shares, 2021
13.8.4 Product Benchmarking
13.8.5 Recent Developments
13.9 Sanofi
13.9.1 Company Snapshot
13.9.2 Company Overview
13.9.3 Financial Analysis
13.9.3.1 Net Revenue, 2017-2021
13.9.3.2 Regional Revenue/Market Shares, 2021
13.9.3.3 Segmental Revenue/Market Shares, 2021
13.9.4 Product Benchmarking
13.9.5 Recent Developments
13.10 Novo Holdings A/S (Novo Nordisk A/S)
13.10.1 Company Snapshot
13.10.2 Company Overview
13.10.3 Financial Analysis
13.10.3.1 Net Revenue, 2017-2021
13.10.3.2 Regional Revenue/Market Shares, 2020
13.10.3.3 Segmental Revenue/Market Shares, 2020
13.10.4 Product Benchmarking
13.10.5 Recent Developments
13.11 Takeda Pharmaceutical Company Limited
13.11.1 Company Snapshot
13.11.2 Company Overview
13.11.3 Financial Analysis
13.11.3.1 Net Revenue, 2017-2021
13.11.3.2 Regional Revenue/Market Shares, 2020
13.11.3.3 Segmental Revenue/Market Shares, 2020
13.11.4 Product Benchmarking
13.12 Eli Lilly and Company
13.12.1 Company Snapshot
13.12.2 Company Overview
13.12.3 Financial Analysis
13.12.3.1 Net Revenue, 2017-2021
13.12.3.2 Regional Revenue/Market Shares, 2020
13.12.4 Product Benchmarking
13.12.5 Recent Developments
13.13 Amgen Inc.
13.13.1 Company Snapshot
13.13.2 Company Overview
13.13.3 Financial Analysis
13.13.3.1 Net Revenue, 2017-2021
13.13.3.2 Regional Revenue Shares, 2021
13.13.3.3 Segment Revenue Shares, 2021
13.13.4 Product Benchmarking
13.13.5 Recent Developments
13.14 Bristol-Myers Squibb Company
13.14.1 Company Snapshot
13.14.2 Company Overview
13.14.3 Financial Analysis
13.14.3.1 Net Revenue, 2017-2021
13.14.3.2 Regional Revenue Shares, 2021
13.14.4 Product Benchmarking
13.14.5 Recent Developments
13.15 Biogen
13.15.1 Company Snapshot
13.15.2 Company Overview
13.15.3 Financial Analysis
13.15.3.1 Net Revenue, 2017-2021
13.15.3.2 Regional Revenue Shares, 2021
13.15.4 Product Benchmarking
13.15.5 Recent Developments
13.16 NuVasive, Inc.
13.16.1 Company Snapshot
13.16.2 Company Overview
13.16.3 Financial Analysis
13.16.3.1 Net Revenue, 2017-2021
13.16.3.2 Regional Revenue Shares, 2021
13.16.3.3 Segment Revenue Shares, 2021
13.16.4 Product Benchmarking
13.17 ORTHOFIX INTERNATIONAL N.V.
13.17.1 Company Snapshot
13.17.2 Company Overview
13.17.3 Financial Analysis
13.17.3.1 Net Revenue, 2017-2021
13.17.3.2 Regional Revenue Shares, 2021
13.17.3.3 Segment Revenue Shares, 2020
13.17.4 Product Benchmarking
13.18 Organogenesis Holdings Inc.
13.18.1 Company Snapshot
13.18.2 Company Overview
13.18.3 Financial Analysis
13.18.3.1 Net Revenue, 2018-2021
13.18.3.2 Segment Revenue Shares, 2021
13.18.4 Product Benchmarking
13.19 AbbVie Inc.
13.19.1 Company Snapshot
13.19.2 Company Overview
13.19.3 Financial Analysis
13.19.3.1 Net Revenue, 2017-2021
13.19.3.2 Regional Revenue Shares, 2021
13.19.3.3 Segment Revenue Shares, 2021
13.19.4 Product Benchmarking
13.19.5 Recent Developments
14 Conclusion and Recommendations
14.1 Concluding Remarks from
14.2 Recommendations for Market Players
List of Tables
Table 1 Global Biologics Market Snapshot, 2022 & 2032 (US$ billion, CAGR %)
Table 2 Global Biologics Market Forecast by Product Type, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 3 Global Biologics examples of US FDA-approved monoclonal antibody present in the market, CAGR%)
Table 4 Global Biologics Market for Monoclonal Antibodies Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 5 Global Biologics Market for Monoclonal Antibodies Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 6 Global Biologics Market for Monoclonal Antibodies Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 7 Global Biologics Market for Monoclonal Antibodies Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 8 Global Biologics Market for Monoclonal Antibodies Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 9 Global Biologics Market for Vaccine Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 10 Global Biologics Market for Vaccine Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 11 Global Biologics Market for Vaccine Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 12 Global Biologics Market for Vaccine Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 13 Global Biologics Market for Vaccine Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 14 Global Biologics Market for Protein Therapeutics Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 15 Global Biologics Market for Protein Therapeutics Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 16 Global Biologics Market for Protein Therapeutics Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 17 Global Biologics Market for Protein Therapeutics Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 18 Global Biologics Market for Protein Therapeutics Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 19 Global Biologics Market for Regenerative Medicines Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR %)
Table 20 Global Biologics Market for Regenerative Medicines Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 21 Global Biologics Market for Regenerative Medicines Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 22 Global Biologics Market for Regenerative Medicines Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 23 Global Biologics Market for Regenerative Medicines Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 24 Global Biologics Market for Fusion Proteins Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR %)
Table 25 Global Biologics Market for Fusion Proteins Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 26 Global Biologics Market for Fusion Proteins Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 27 Global Biologics Market for Fusion Proteins Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 28 Global Biologics Market for Fusion Proteins Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 29 Global Biologics Market Forecast by Application, 2022-2032 (US$ bn, AGR%, CAGR %)
Table 30 Global Biologics Market for Oncology Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 31 Global Biologics Market for Oncology Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 32 Global Biologics Market for Oncology Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 33 Global Biologics Market for Oncology Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 34 Global Biologics Market for Oncology Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 35 Global Biologics Market for Autoimmune Diseases Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 36 Global Biologics Market for Autoimmune Diseases Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 37 Global Biologics Market for Autoimmune diseases Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 38 Global Biologics Market for Autoimmune Diseases Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 39 Global Biologics Market for Autoimmune Diseases Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 40 Global Biologics Market for Infectious Diseases Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 41 Global Biologics Market for Infectious Diseases Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 42 Global Biologics Market for Infectious Diseases Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 43 Global Biologics Market for Infectious Diseases Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 44 Global Biologics Market for Infectious Diseases Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 45 Global Biologics Market for Cardiovascular Diseases Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR %)
Table 46 Global Biologics Market for Cardiovascular Diseases Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 47 Global Biologics Market for Cardiovascular Diseases Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 48 Global Biologics Market for Cardiovascular Diseases Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 49 Global Biologics Market for Cardiovascular Diseases Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 50 Global Biologics Market for Haematological Disorders Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 51 Global Biologics Market for Haematological Disorders Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 52 Global Biologics Market for Haematological Disorders Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 53 Global Biologics Market for Haematological Disorders Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 54 Global Biologics Market for Haematological Disorders Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 55 Global Biologics Market for Others Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR %)
Table 56 Global Biologics Market for Others Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 1 Global Biologics Market for Others Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 57 Global Biologics Market for Others Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 58 Global Biologics Market for Others Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 59 Global Biologics Market Forecast by Manufacturing, 2022-2032 (US$ bn, AGR%, CAGR %)
Table 60 Global Biologics Market for In-house Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR %)
Table 61 Global Biologics Market for In-house Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 62 Global Biologics Market for In-house Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 63 Global Biologics Market for In-house Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 64 Global Biologics Market for In-house Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 65 Global Biologics Market for Outsourced Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR %)
Table 66 Global Biologics Market for outsourced Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 67 Global Biologics Market for Outsourced Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 68 Global Biologics Market for Outsourced Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 69 Global Biologics Market for Outsourced Segment Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 70 Global Biologics Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 71 Global Biologics Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 72 Global Biologics Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 73 Global Biologics Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 74 Global Biologics Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 75 North America Biologics Market Forecast by Country, 2022-2032 (US$ bn, AGR%, CAGR %)
Table 76 North America Biologics Market Forecast by Product Type, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 77 North America Biologics Market Forecast by Product Type, 2022-2032 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 78 North America Biologics Market Forecast by Product Type, 2022-2032 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 79 North America Biologics Market Forecast by Product Types, 2022-2032 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 80 North America Biologics Market Forecast by Product Type, 2022-2032 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 81 North America Biologics Market Forecast by Application, 2022-2032 (US$ bn, AGR%, CAGR %)
Table 82 North America Biologics Market Forecast by Application, 2022-2032 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 83 North America Biologics Market Forecast by Application, 2022-2032 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 84 North America Biologics Market Forecast by Product Types, 2022-2032 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 85 North America Biologics Market Forecast by Application, 2022-2032 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 86 North America Biologics Market Forecast by Manufacturing, 2022-2032 (US$ bn, AGR%, CAGR %)
Table 87 North America Biologics Market Forecast by Manufacturing, 2022-2032 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 88 North America Biologics Market Forecast by Manufacturing, 2022-2032 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 89 North America Biologics Market Forecast by Manufacturing, 2022-2032 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 90 North America Biologics Market Forecast by Manufacturing, 2022-2032 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 91 U.S. Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 92 U.S. Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 93 U.S. Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 94 U.S. Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 95 U.S. Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 96 Canada Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 97 Canada Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 98 Canada Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 99 Canada Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 100 Canada Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 101 Europe Biologics Market Forecast by Country, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 102 Europe Biologics Market Forecast by Product Type, 2022-2032 (US$ bn, AGR%, CAGR %)
Table 103 Europe Biologics Market Forecast by Product Type, 2022-2032 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 104 Europe Biologics Market Forecast by Product Type, 2022-2032 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 105 Europe Biologics Market Forecast by Product Types, 2022-2032 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 106 Europe Biologics Market Forecast by Product Type, 2022-2032 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 107 Europe Biologics Market Forecast by Application, 2022-2032 (US$ bn, AGR%, CAGR %)
Table 108 Europe Biologics Market Forecast by Application, 2022-2032 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 109 Europe Biologics Market Forecast by Application, 2022-2032 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 110 Europe Biologics Market Forecast by Application, 2022-2032 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 111 Europe Biologics Market Forecast by Application, 2022-2032 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 112 Europe Biologics Market Forecast by Manufacturing, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 113 Europe Biologics Market Forecast by Manufacturing, 2022-2032 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 114 Europe Biologics Market Forecast by Manufacturing, 2022-2032 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 115 Europe Biologics Market Forecast by Manufacturing, 2022-2032 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 116 Europe Biologics Market Forecast by Manufacturing, 2022-2032 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 117 Germany Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 118 Germany Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 119 Germany Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 120 Germany Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 121 Germany Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 122 U.K. Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 123 U.K. Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 124 U.K. Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 125 U.K. Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 126 U.K. Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 127 France Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 128 France Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 129 France Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 130 France Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 131 France Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 132 Italy Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR %)
Table 133 Italy Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 134 Italy Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 135 Italy Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 136 Italy Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 137 Spain Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 138 Spain Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 139 Spain Biologics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 140 Sp
